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Intracellular reduced folate exists as a “pool” of more than 6 interconvertable forms. One of these forms, 5,10 methylenete-
trahydrofolic acid (CH2THF), is the key one-carbon donor and reduced folate substrate for thymidylate synthase (TS). This
pathway has been an important target for chemotherapy as it provides one of the necessary nucleotide substrates for DNA
synthesis. The ﬂuoropyrimidine 5-ﬂuorouracil (5-FU) exerts its main cytotoxic activity through TS inhibition. Leucovorin
(5-formyltetrahydrofolate; LV) has been used to increase the intracellular reduced folate pools and enhance TS inhibition.
However, it must be metabolized within the cell through multiple intracellular enzymatic steps to form CH2THF. CoFactor
(USAN fotrexorin calcium, (dl)-5,10,-methylenepteroyl-monoglutamate calcium salt) is a reduced folate that potentiates 5-FU
cytotoxicity. According to early clinical trials, when 5-FU is modulated by CoFactor instead of LV, there is greater anti-tumor
activity and less toxicity. This review presents the emerging role of CoFactor in colorectal and nongastrointestinal malignancies.
1. Rationale
1.1. Folate Metabolism. Intracellular reduced folate exists as
a “pool” of more than 6 interconvertable forms. One of
these forms, 5,10 methylenetetrahydrofolic acid (CH2THF),
is the key one-carbon donor and reduced folate substrate
for thymidylate synthase (TS), the enzyme that catalyzes the
methylation of deoxyuridine-5 -monophosphate (dUMP)
to deoxythymidine-5 -monophosphate (dTMP). This enzy-
matic pathway provides one of the necessary nucleotide
substrates for DNA synthesis. TS has, therefore, been an
important target for cancer chemotherapy [1, 2].
The ﬂuoropyrimidine 5-ﬂuorouracil (5-FU) exerts its
cytotoxic activity, at least in part, through TS inhibition.
Cytotoxicity is achieved with the formation of 5-FU metabo-
lite, a ternary complex consisting of ﬂuorodeoxyuridine
monophosphate (FdUMP), TS, and the reduced folate
CH2THF [3–5]. However, since TS displays a Bi Bi kinetic
mechanism of substrate recognition and binding, the pres-
enceofCH2THFasaTScosubstrateismandatoryeveninthe
absence of 5-FU (where no antineoplastic action is expected)
[6–8].
Historically, leucovorin (5-formyltetrahydrofolate; LV)
has been used to increase the intracellular reduced folate
pools and enhance TS enzyme inhibition [7]. However,
LV must be metabolized within the cell through multiple
intracellular enzymatic steps to form CH2THF [9–12]. In
general, CH2THF levels are relatively low, in the range
of approximately 0.1–0.5μmol/L in normal cells, and even
lower in human cancer biopsy tissues. While treatment with
LV results in an approximately 2-fold increase in CH2THF
[13, 14], maximum ternary complex formation is generally
achieved at CH2THF concentrations approaching 12μmol/L
[13].
Individual tumor metabolism of LV to tetrahydrofolate
and, ultimately, to CH2THF is unpredictable, and CH2THF2 Journal of Oncology
levels are typically among the lowest of the activated
intracellular reduced folate forms [15, 16]. However, it is
clear that high intratumoral levels of CH2THF allow for
greater TS inhibition [17]. Preclinical and clinical investiga-
tions have consistently shown that resistance of tumors to 5-
FU is associated, at least in part, with decreased intratumoral
reduced folate levels, typically through decreased folylpolyg-
lutamylation [17–20].
Thus, direct administration of the essential reduced
folate CH2THF in place of LV might oﬀer signiﬁcant
advantages with respect to clinical activity. This is supported
by the fact that the essential reduced folate CH2THF is
the direct cosubstrate of TS. LV, on the other hand, is a
precursoranditsbioavailabilityispartiallyexploitedbyother
enzymes as well, since it is also the one carbon donor for
other enzymatic pathways and provides several necessary
substrates for DNA synthesis. This may also be linked to
the fact that at CH2THF (monoglutamate) concentrations of
above 1.0 microM, dUMP interference is nearly abolished, as
folate levels inﬂuence the competitive basis and speciﬁcity of
dUMP-mediated changes in the ternary complex formation
[5].
1.2. CoFactor. CoFactor (USAN fotrexorin calcium, also
known as (dl)-5,10,-methylenepteroyl-monoglutamate cal-
cium salt and trivially as racemic CH2THF) is a reduced
folate.Inthisprotocol,CH2THFreferstothedrugsubstance,
and CoFactor refers to the clinical formulation. The drug
is supplied as 100mg of lyophilized powder in 10mL vials.
The lyophilized powder is reconstituted immediately before
use with 10mL sterile water for injection [21]. It should be
pointed out that CH2THF acts as a cosubstrate, rather than
a true cofactor, since it does not bound to the apoenzyme
in order to form a holoenzyme, but instead must be present
in stoichiometric concentrations to allow the conversion
of an adequate amount of dUMP to its product. In order
that the physiologic reaction as well as 5-FU action takes
place, CH2THF must be present in conspicuous in situ
concentrations within the cells.
2.PreclinicalStudies
CoFactor has been shown to potentiate 5-FU cytotoxicity in
numerous in vivo animal models of colorectal, pancreatic,
and gastric cancers. Comparative analyses in “tumor take”
models have demonstrated that CoFactor combined with
5-FU is signiﬁcantly more eﬀective in terms of synergistic
antitumor activity when compared to LV/5-FU [22].
The combination of CoFactor and 5-FU/bevacizumab
was also studied in an in vivo model using the HT-29
xenograft. CoFactor and LV signiﬁcantly enhanced tumor
inhibition and animal survival when added to 5-FU/bevac-
izumab, with the CoFactor arm appearing slightly better,
albeit nonsigniﬁcant, than the LV arm [24]. A similar study
using the DLD-1 human colorectal cancer xenograft model
was conducted with the combination of 5-FU/oxaliplatin
alone or in combination with LV or CoFactor. The CoFactor
triple combination was clearly superior in inhibiting tumor
growth, which translated in improved animal survival [23].
Regimens, protocols, and results of the preclinical studies
have been summarized in Table 1.
3.ClinicalStudies
3.1. Phase I/II Study in Patients with Advanced Cancers. In a
phase I/II trial in patients with solid tumors, CoFactor was
administered as intravenous (I.V.) bolus over 2–3 minutes at
2 dose levels, 100 mg or 200mg, followed 20 minutes later by
anI.V.bolusof5-FU.Thetreatmentwasadministeredweekly
[25].
Toxicities were mild, with only 2 of 17 subjects showing
grade 3/4 gastrointestinal toxicity at the highest 5-FU dose
(450–500mg/m2) with the 200mg dose of CH2THF. Mild
conjunctivitis, however, was seen in a majority of subjects at
that level, and grade 1/2 leucopenia was observed in only 6 of
the 17 subjects.
Serial liver tumor biopsies obtained percutaneously in
17 patients after administration of the ﬁrst dose of 5-
FU/CoFactor conﬁrmed potent inhibition of TS. Antitumor
activity was observed: of 58 patients evaluable for tumor
response, 17 exhibited a partial or complete response (29%).
Clinical activity was principally seen in colorectal (n = 35;
33 evaluable, 7 responses), breast (n = 9; 5 responses),
pancreatic (n = 5; 2 responses), and gastric (n = 9;
3 responses) cancers. No activity was seen in gallbladder
cancer (n = 3; 2 evaluable, 0 responses). The median time
to progression (TTP) for all patients was 265 days (range:
21–2221 days). In patients receiving 100mg CoFactor/5-FU,
the median time to progression was 443 days (range: 90–
2221 days), which was signiﬁcantly longer compared to 238
days (range: 90–1149 days) for patients receiving 200mg
CoFactor/5-FU (P = .0264).
Based on the report of reduced toxicity, the apparent
greater activity reﬂected in TTP, and the adequate degree
of inhibition of tumor TS activity, the dose of 60mg/m2
(approximating the 100-mg dose) was selected as the phase
II dose for CoFactor in combination with 5-FU [25].
3.2. Phase II Trial in Previously Untreated Metastatic Col-
orectal Cancer. A single-arm phase II clinical trial was con-
ducted in 50 patients with previously untreated metastatic
colorectal adenocarcinoma [26]. Dosing of CoFactor was
based on the lower dose in the phase I study and
administered as 60-mg/m2 I.V. bolus 20 minutes before 5-
FU administration. 5-FU was administered at a dose of
450mg/m2 bolus weekly for 6 weeks of a 7-week treatment
cycle. Clinical response was evaluated after completion of
2 consecutive cycles and was based on objective tumor
response (WHO criteria). The objective response rate
(complete response plus partial response) was 35% (16
of 46 patients; 95% conﬁdence interval, 21.4%–50.2%) as
assessed by blinded third-party review. Median TTP was
162 days (approximately 5.3 months) from the begin-
ning of treatment. Median overall survival was 459 days
(approximately 15.1 months) as estimated by Kaplan-Meier
projections.Journal of Oncology 3
Table 1: Preclinical studies of CoFactor.
Preclinical study Study
conducted on Regimen Protocol Results
Bjelogrli´ ce ta l .
(2007) [22]
human colon
cancer cells:
LS-174 and
HT-29
CoFactor, LV,
CoFactor/5-FU,
LV/5-FU
Single agent concentrations ranged
from 0.1 to 300 microM for 5-FU,
CoFactor, and LV. In combined
treatment, 5-FU concentration was
matched with CoFactor or LV. Sulfo-
rodamine B cytotoxic test was used.
CoFactor showed cytotoxic eﬀect on
both cell lines. Addition of LV did not
change 5-FU cytotoxicity, whereas,
the combination of 5-FU with Co-
Factor revealed synergistic and add-
itive interactions.
Cantwell and
Robbins (2005)
[23]
athymic nude
mice
LV- or CoFactor-
regimens of 5-FU
combined with:
irinotecan,
oxaliplatin,
bevacizumab or
gemcitabine
A human tumor xenotransplant
model for colorectaland pancreatic
cancerinathymicnudemicewasused
as well as an in vivo Balb/c systemic
toxicity model.
CoFactor increases the therapeutic
index of 5-FU- regimens since it
induces equivalent or better antitu
mor response, less systemic toxicity
and less weight loss as compared to
LV-containing regimens.
Cantwell et al.
(2004) [24]
6–8 week old
nude mice
inoculated
subcutaneously
with 2 × 106
HT-29 cells.
Combinations of
5-FU, CoFactor,
leucovorin, and
αVEGF (recomb-
inant antibody,
angiogenesis
inhibitor)
When tumors reached 0.1–0.3cm3 in
volume, drugs were administered in-
traperitoneally. All drugs were dosed
daily for 5 consecutive days with the
exception of αVEGF, dosed on day
1. CoFactor or LV were injected 20
minutes prior to 5-FU.
Mean tumor volumes after Co-
Factor/VEGF/5-FU combination we-
re smaller than after 5-FU alone, Co-
Factor/FU, or leucovorin/5-FU. There
was greater survival of mice treated
with CoFactor/5-FU either with or
without αVEGF compared to mice
treated with only 5-FU.
The combination of CoFactor and 5-FU was well tol-
erated, and the safety proﬁle was quite manageable. No
cases of drug-related grade 3/4 gastrointestinal toxicity were
observed. The incidence of myelosuppression was low, and
granulocyte nadirs were only mildly decreased from baseline
at the end of each treatment cycle. The highest individual
grade of neutropenia was grade 2, which occurred in only
one patient, and only one episode of grade 1 thrombocy-
topenia was recorded. Overall, this study suggested that this
combination was associated with an improved safety proﬁle
when compared to 5-FU/LV [26].
3.3. Treatment after 5-Fluorouracil/CoFactor. Fifty patients
completed CoFactor plus 5-FU treatment in the phase II
clinical trial and continued with second-line therapy [27].
Four underwent partial liver resection for potential cure,
and 29 patients received chemotherapy with irinotecan or
oxaliplatin alone or in combination with 5-FU/LV as well
as other agents. Seventeen patients received no poststudy
intervention. Out of a total of 29 patients who received post-
study chemotherapy, 4 (14%) exhibited objective response,
including one patient with complete response. Median
overall survival, measured from the beginning of ﬁrst-line
treatment, was 23 months for patients who received second-
line treatment, including patients who underwent surgical
resection.
The combination of 5-FU and Cofactor has also been
used as neoadjuvant chemotherapy prior to the resection of
hepatic metastasis in colon cancer in an eﬀort to reduce the
necessary doses of 5-FU and related side eﬀects [28]. The
usefulness of such a combination in elderly patients should
be explored further in future studies.
3.4. Randomized Controlled Phase IIB Trial with Previously
Untreated Metastatic Colorectal Cancer (03-CoFactor Trial).
A recently completed randomized phase IIB study (study 03)
compares CoFactor with LV, combined with infusional 5-FU,
in 300 patients with previously untreated metastatic CRC.
The primary endpoint of this study is the incidence of severe
toxicity. The secondary endpoint of antitumor eﬃcacy will
bequalityassuredbyanindependentradiologicreview.After
the initial 150 patients had been enrolled onto the study, the
Drug Safety Monitoring Board reviewed all of the interim
data and recommended that the study continue as planned
and ﬁnal results are expected [29].
3.5. Randomized Phase III Trial in Metastatic Colorectal
Carcinoma. This phase III study investigated the safety and
eﬃcacy of CoFactor in combination with 5-FU and beva-
cizumabversusLVplus5-FUplusbevacizumabinmetastatic
colorectal carcinoma [30]. This was the ﬁrst clinical trial
that combined CoFactor and bevacizumab. The interim
analysis showed that overall safety in patients receiving
b o l u sC o f a c t o r / 5 - F Up l u sb e v a c i z u m a bw a sc o m p a r a b l et o
that in patients treated with LV/5-FU plus bevacizumab,
constituting it a useful alternative. Results on progression-
free survival and overall response rates are expected upon
completion of the study [31].
3.6. Phase II Trials of CoFactor in Patients with Other
Malignancies. The promising results of the initial studies
that combined CoFactor and 5-FU in metastatic colorectal
cancer led to the development of trials concerning the use
of CoFactor in other malignancies as well. The ongoing
Stewart et al. trial is a single-arm phase II study assessing4 Journal of Oncology
the eﬃcacy and safety of weekly bolus infusions in advanced
breast cancer patients who failed prior treatment with
anthracyclines and taxanes. Preliminary data on 21 patients
showed that the CoFactor/5-FU combination is a highly
eﬀective,safe,andverywell-toleratedtreatmentinmetastatic
breast cancer. With the use of anthracycline and taxanes-
based regimens in the adjuvant setting, this combination
could be a good treatment option in advanced disease [32].
A phase I/II clinical trial conducted in Europe studied the
use of CoFactor in pancreatic cancer and demonstrated
that CoFactor combined with 5-FU showed clinical beneﬁt,
deﬁned as stable disease or tumor response, in 40% of
patients. A phase III trial was planned but has not been
performed yet [33].
3.7. Side Eﬀects. Regarding adverse events reported with
the administration of CoFactor/5-FU, the most frequent
events are diarrhea, nausea, fatigue, and vomiting, but
these are comparable to the adverse events noticed with
LV/5-FU regimens [30–32]. Furthermore, it is not possible
to distinguish whether these side eﬀects derive from the
CoFactor itself or the chemotherapy coadministered. After
searching the published literature, we found no reports on
possible drug interactions with other drugs aside from those
with 5-FU that have been described above.
It should be noted that CH2THF cannot by itself be
considered “toxic” unless referring to overdosage and/or
side eﬀects not related to the coadministration of 5-FU.
They exert an ancillary action with 5-FU allowing TS
inhibition to reach full completion, as it is needed for this
reaction [5]. However, since folates have a major role in
cell growth by serving as one-carbon unit donors for dTMP
and purine ring biosynthesis, it can be argued that folate
supplementation may fuel tumor growth, even in preclinical
stages of malignancy. Therefore, folate administration must
be performed with caution, and large trials are needed to
clarify this subject.
4. Conclusion
AscomparedtoLV,CoFactorexhibitsasimilarmechanismof
action but is associated with reduced metabolic complexity,
greater 5-FU antitumor activity, and more limited systemic
5-FU toxicity. It is a necessary cosubstrate for TS, which
needs its CH2THF cosubstrate for 5-FU to gain full activity.
It has been, therefore, proposed that CoFactor could be used
instead of LV in current chemotherapy regimens containing
5-FU. CoFactor is not toxic per se and can be used when
5-FU is administered as a necessary part of the therapeutic
protocol. The clinical eﬃcacy in combination with the low
toxicity of the 5-FU/CoFactor regimen suggests it might be
a preferable initial treatment for metastatic colorectal cancer,
especially in patients who require a less aggressive treatment.
The latter may also enhance patient compliance. Preliminary
data of ongoing studies show promising results of CoFactor
in other malignancies as well. More large-scale randomized
trials are needed to fully explore the potential of this novel
agent.
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